Abbott Laboratories
 (ABT)

- NYSE
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Oct. 17, 2012, 3:25 PM

    Abbott Laboratories (ABT -4%) says it's laying off about 550 workers and plans several hundred more layoffs throughout 2013, citing "evolving business needs." The disclosure comes on the back of a Q3 earnings report earlier today showing surging profit amid a double-digit percentage fall in expenses.

    | Oct. 17, 2012, 3:25 PM | 5 Comments
  • Oct. 17, 2012, 9:00 AM

    More on Abbott Labs (ABT) Q3: net profit soars to $1.94B from $303M as operating margin soars to 20.4% from 6.1%. Total op costs -16%, with last year's SG&A expenses including $1.5B of litigation reserves. Abbot narrows FY EPS guidance to $5.06-$5.08 from $5-$5.10 previously and vs. consensus of $5.06. Says the separation into two companies is on track for Jan. 1.

    | Oct. 17, 2012, 9:00 AM
  • Oct. 17, 2012, 7:46 AM
    Abbott Laboratories (ABT): Q3 EPS of $1.30 beats by $0.02. Revenue of $9.77B (+2% Y/Y) misses by $160M. (PR)
    | Oct. 17, 2012, 7:46 AM
  • Oct. 17, 2012, 12:05 AM
    Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, BLK, CHKP, CMA, DGX, DOV, HAL, KCG, MMR, MTB, PEP, STJ, STP, SWK, TXT, USB
    | Oct. 17, 2012, 12:05 AM
  • Oct. 16, 2012, 5:30 PM
    Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, BLK, CHKP, CMA, DGX, DOV, HAL, KCG, MMR, MTB, PEP, STJ, STP, SWK, TXT, USB
    | Oct. 16, 2012, 5:30 PM | 3 Comments
  • Oct. 16, 2012, 12:36 PM

    Achillion (ACHN +4.6%) gains on a price target increase to $17 from $12 at Deutsche Bank. The firm says liver abstracts from Bristol-Myers (BMY +0.6%) and Abbott (ABT +0.1%) bode well for the future success of ACHN's two drug combo regimens for the treatment of hepatitus C virus. The firm made similar comments yesterday about Gilead (GILD +1.6%).

    | Oct. 16, 2012, 12:36 PM
  • Oct. 15, 2012, 1:50 PM
    Gilead (GILD -0.9%) slips a bit today after Bristol-Myers (BMY +3.2%) and Abbott (ABT +3.7%) both reported favorable study results for their HCV drugs (I,II). Deutsche Bank defends the stock , saying the results of these studies show that utilizing different drug combinations yields more effective HCV treatments, and that this data actually bodes well for GILD's 7977-based class combos, for which it expects the drug developer to yield similar results.
    | Oct. 15, 2012, 1:50 PM
  • Oct. 15, 2012, 12:58 PM

    Abbott (ABT +3.4%) moves up after initial results from its "Aviator" Phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C indicated that 99% of the "treatment naive" HCV patients - those who had never been previously treated for the virus - showed a sustained virological response. Additionally, 93% of patients in the study who had previously been unsuccessfully treated for HCV also showed sustained virological response.

    | Oct. 15, 2012, 12:58 PM | 2 Comments
  • Sep. 28, 2012, 2:13 PM

    The FDA is expanding the approved use of Abbott's (ABT -1%) Humira to include treatment of moderate-to-severe ulcerative colitis in adults, when immunosuppressant medicines have not worked. The drug is currently approved for use in reducing the signs and symptoms of rheumatoid arthritis.

    | Sep. 28, 2012, 2:13 PM
  • Sep. 26, 2012, 11:37 AM

    Abbott (ABT -0.4%) says its humanised monoclonal antibody for the treatment of glioma has been granted orphan designation by the European Commission. Glioma affects approximately 1 in 10K people in the European Union, or the equivalent of a total of around 51K people.

    | Sep. 26, 2012, 11:37 AM
  • Sep. 26, 2012, 7:56 AM

    The EU proposes tougher standards on medical devices and implants after investigations showed hundreds of thousands of women were at risk from substandard silicone implants. Independent assessment of manufacturers and increased product testing could result from the new legislation.

    | Sep. 26, 2012, 7:56 AM | 4 Comments
  • Sep. 20, 2012, 6:05 AM

    Ten major pharmaceutical firms, including AstraZeneca (AZN), Eli Lilly (LLY), GSK, J&J (JNJ) and Pfizer (PFE), have formed a non-profit organization called TransCelerate BioPharma to cooperate on research as they look to speed up drug development. TransCelerate will start by making clinical trials more efficient, including standardizing the way data is recorded to make it easier for regulators.

    | Sep. 20, 2012, 6:05 AM
  • Sep. 13, 2012, 11:07 AM
    Abbott Laboratories (ABT) declares $0.51/share quarterly dividend, in line with previous. Forward yield 2.99%. For shareholders of record Oct 15. Payable Nov 15. Ex-div date Oct 11. (PR)
    | Sep. 13, 2012, 11:07 AM
  • Aug. 28, 2012, 1:50 PM
    An FDA panel has voted 3-14 that Abbott (ABT) has not found right dose for its irritable bowel syndrome drug Humira. Last week, FDA staff had questioned whether Humira had a real benefit for people with the disease who had already tried other treatments.
    | Aug. 28, 2012, 1:50 PM | 2 Comments
  • Aug. 28, 2012, 9:03 AM

    Abbott Labs (ABT) receives the EU CE's mark for the second generation of its Architect assay, which measures testosterone levels and has improved sensitivity. (PR)

    | Aug. 28, 2012, 9:03 AM
  • Aug. 26, 2012, 5:38 AM
    FDA staff are skeptical that Abbott's (ABT) Humira drug, which is already cleared for rheumatoid arthritis, is effective in treating ulcerative colitis in patients who don't respond to conventional medicines. Although two trials of Humira met the studies' goals, on Friday the FDA questioned the "clinical meaningfulness" of the results. An advisory panel is due to meet on Tuesday.
    | Aug. 26, 2012, 5:38 AM
Company Description
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.